Why This Biotech Company Could Be a Growth Stock Powerhouse

There is no sugarcoating it: Vertex Pharmaceuticals (NASDAQ: VRTX) has faced significant issues this year that have sunk its stock price. The company's shares are down 2% year-to-date, while the S&P 500 is up 9%. But none of that means the biotech company is no longer attractive.In fact, Vertex's challenges this year might have created a solid entry point for a company that can be an excellent growth stock in the next five years and perhaps beyond. Here's why investors shouldn't give up on this biotech stock just yet.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool